Table 1 Characteristics of epithelioid hemangioendothelioma (EHE) in the liver, lungs, soft tissues, and bone (common presentations)
From: Epithelioid hemangioendothelioma of the thyroid: a case report
Site [ref] | Sex | Multicentric | Metastasis | Management | Survival rate (5 years) | Prognostic factors | Treatment | |
|---|---|---|---|---|---|---|---|---|
Rate (%) | Site | |||||||
Liver | M < F | 87% | 36.6 | Lungs, peritoneum, lymph nodes, bone | Transplantation, resection, medication, radiotherapy, embolization | 41 | Extrahepatic disease, vascular invasion | Chemotherapy (doxorubicin, cisplatin, 5FU), targeted therapy (sorafenib, pazopanib), IFN α-2b, thalidomide, lenalidomide |
Lung | M < F | 91% | 50.5 | Liver, pleura, lymph nodes | Lung resection, medication | 60 | Hemoptysis, pleural effusion, anemia, thoracic symptoms | Chemotherapy (carboplatin, paclitaxel), targeted therapy (bevacizumab, pazopanib), IFN α-2b, thalidomide, lenalidomide |
Soft tissue | M < F | 4% | 22 | Lungs, lymph nodes, liver, bone | Surgical resection, chemotherapy, radiotherapy | 81 | Mitotic activity, size | ND |
Bone | M > F | >50% | ND | Uncommon | Wide surgical resection, limited surgery, radiofrequency ablation, radiotherapy | 92 (10 years) | Visceral involvement | |